Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Clinical Research Standardized Reading Procedures iRECIST RECIST Research with mint mintLesion

Related Resources

Related Resources

MROC: The Impact of mpMRI on the Staging and Management of Patients with Suspected or Confirmed OC

Funded by the National Institute of Health Research (NIHR) and sponsored by the Imperial College London, the MROC study boasts impressive figures: 645…

AI-powered quantification of bone metastasis in prostate cancer

Prostate cancer is the second most common cancer among men, and there are now effective treatments for the disease. New therapies available on the…

Radiomics - the next era of possibilities in Precision Medicine

Traditionally medical image analysis has been done through visual interpretation of static images. In the past decade, with the advent of…